Adaptive Biotechnologies director Peter M. Neupert disposes of 124,690 common shares for $3.14 million

Reuters2026/08/20 00:08

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Adaptive Biotechnologies director Peter M. Neupert reported option exercise and share sales dated Aug. 17, 2026.
Exercised 15,000 stock options at $6.32, then sold 124,690 shares at weighted-average prices near $25.10-$25.23.
Directly held 130,625 shares following the transactions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adaptive Biotechnologies Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001237566-26-000003), on August 19, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

On Wednesday, IBM announced that it has successfully connected and cooled two cryogenic modules within the same operating environment, and has completed preliminary testing. The company stated that this modular architecture is designed to scale into an ultra-low temperature shared system capable of connecting hundreds of quantum chips, marking a key step toward the launch of IBM Quantum Starling in 2029.

智通财经•2026/08/20 01:06